Tela Bio, Inc. TELA
We take great care to ensure that the data presented and summarized in this overview for TELA Bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TELA
View all-
Essex Woodlands Management, Inc. The Woodlands, TX4.11MShares$11.3 Million2.98% of portfolio
-
Aigh Capital Management LLC Baltimore, MD2.47MShares$6.82 Million2.52% of portfolio
-
Orbimed Advisors LLC San Diego, CA2.16MShares$5.96 Million0.13% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT1.92MShares$5.29 Million0.29% of portfolio
-
Silverarc Capital Management, LLC1.12MShares$3.1 Million0.71% of portfolio
-
Stonepine Capital Management, LLC Bend, OR1.11MShares$3.06 Million1.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA904KShares$2.49 Million0.0% of portfolio
-
Citigroup Inc750KShares$2.07 Million0.0% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA747KShares$2.06 Million3.91% of portfolio
-
Black Rock Inc. New York, NY567KShares$1.57 Million0.0% of portfolio
Latest Institutional Activity in TELA
Top Purchases
Top Sells
About TELA
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Insider Transactions at TELA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 24
2024
|
Gregory A. Firestone Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
6,666
+10.42%
|
$13,332
$2.25 P/Share
|
|
Oct 24
2024
|
Antony Koblish Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
88,888
+16.23%
|
$177,776
$2.25 P/Share
|
|
Oct 24
2024
|
Paul Talmo Chief Technology Officer |
BUY
Open market or private purchase
|
Direct |
22,222
+19.61%
|
$44,444
$2.25 P/Share
|
|
Oct 24
2024
|
Roberto Cuca COO and CFO |
BUY
Open market or private purchase
|
Direct |
64,444
+29.32%
|
$128,888
$2.25 P/Share
|
|
Aug 03
2024
|
Gregory A. Firestone Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,093
-2.11%
|
$4,372
$4.25 P/Share
|
|
Jul 02
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
36,600
-1.5%
|
$146,400
$4.54 P/Share
|
|
Jul 01
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
13,700
-0.56%
|
$54,800
$4.68 P/Share
|
|
Jun 28
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
378,000
-13.33%
|
$1,512,000
$4.74 P/Share
|
|
Jun 04
2024
|
Federica F. O'Brien Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,250
+28.77%
|
-
|
|
Jun 04
2024
|
Vincent J Burgess Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,250
+21.65%
|
-
|
|
Jun 04
2024
|
Lisa N Colleran Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,250
+28.77%
|
-
|
|
Jun 04
2024
|
Kurt Azarbarzin Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,250
+28.77%
|
-
|
|
Jun 04
2024
|
Douglas G Evans Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,250
+28.77%
|
-
|
|
Jun 04
2024
|
Jeffrey Blizard Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,375
+50.0%
|
-
|
|
Mar 31
2024
|
Antony Koblish Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
385
-0.1%
|
$1,925
$5.67 P/Share
|
|
Mar 31
2024
|
Gregory A. Firestone Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
119
-0.23%
|
$595
$5.67 P/Share
|
|
Mar 31
2024
|
Peter C. Murphy Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
163
-0.34%
|
$815
$5.67 P/Share
|
|
Mar 31
2024
|
Megan Smeykal Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
96
-0.33%
|
$480
$5.67 P/Share
|
|
Mar 31
2024
|
Paul Talmo Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
190
-0.28%
|
$950
$5.67 P/Share
|
|
Feb 24
2024
|
Paul Talmo Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,049
-1.5%
|
$7,343
$7.07 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 189K shares |
|---|---|
| Open market or private purchase | 185K shares |
| Open market or private sale | 428K shares |
|---|---|
| Payment of exercise price or tax liability | 25.1K shares |